Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab.
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
To evaluate the ability of tocilizumab (a humanised anti-IL-6 receptor antibody) monotherapy
to inhibit progression of structural joint damage in patients with RA.
[1
]
Laboratory of Immune Regulation, Graduate School of Frontier Biosciences, Osaka University
1-3, Yamada-oka, Suita, Osaka, 565-0871, Japan. norihiro@fbs.osaka-u.ac.jp